Kim, H.; Elkins, E.; Islam, R.; Cao, B.; Abbes, N.; Battles, K.; Kim, S.; Kim, S.; Williams, C.
Silmitasertib (CX-4945) Disrupts ERα/HSP90 Interaction and Drives Proteolysis through the Disruption of CK2β Function in Breast Cancer Cells. Cancers 2024, 16, 2501.
https://doi.org/10.3390/cancers16142501
AMA Style
Kim H, Elkins E, Islam R, Cao B, Abbes N, Battles K, Kim S, Kim S, Williams C.
Silmitasertib (CX-4945) Disrupts ERα/HSP90 Interaction and Drives Proteolysis through the Disruption of CK2β Function in Breast Cancer Cells. Cancers. 2024; 16(14):2501.
https://doi.org/10.3390/cancers16142501
Chicago/Turabian Style
Kim, Hogyoung, Emma Elkins, Rahib Islam, Bo Cao, Nour Abbes, Kaela Battles, Sihyoung Kim, Sichan Kim, and Christopher Williams.
2024. "Silmitasertib (CX-4945) Disrupts ERα/HSP90 Interaction and Drives Proteolysis through the Disruption of CK2β Function in Breast Cancer Cells" Cancers 16, no. 14: 2501.
https://doi.org/10.3390/cancers16142501
APA Style
Kim, H., Elkins, E., Islam, R., Cao, B., Abbes, N., Battles, K., Kim, S., Kim, S., & Williams, C.
(2024). Silmitasertib (CX-4945) Disrupts ERα/HSP90 Interaction and Drives Proteolysis through the Disruption of CK2β Function in Breast Cancer Cells. Cancers, 16(14), 2501.
https://doi.org/10.3390/cancers16142501